Novartis announces Oncology head to retire
December 15 2017 - 1:00AM
YASTEST
Novartis International AG / Novartis announces Oncology head to
retire . Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this
announcement.
Basel, December 15, 2017 -
Novartis announced today that Bruno Strigini, CEO Novartis Oncology
has decided to retire from Novartis and the industry for personal
reasons.
Joseph Jimenez, CEO of Novartis, said: "I'd like
to thank Bruno Strigini for his contributions and achievements. He
has navigated the business unit through the Gleevec® patent
expiration and has led the successful integration of the GSK
Oncology Product Portfolio acquired in 2015. I wish him the best
for his future."
Bruno Strigini will step back from the Executive
Committee of Novartis by December 31, 2017 and will fully handover
in early 2018. Novartis will announce his successor in due
time.
Disclaimer
This press release contains forward-looking statements within the
meaning of the US Private Securities Litigation Reform Act of 1995,
which can generally be identified by words such as "to retire,"
"will," or similar expressions. You should not place undue reliance
on these statements. Such forward-looking statements reflect the
current views of the Group regarding future events, and involve
known and unknown risks, uncertainties and other factors that may
cause actual results to be materially different from any future
results expressed or implied by such statements. There can be no
guarantee that Novartis will be commercially successful in the
future, or achieve any particular financial results. In particular,
our expectations could be affected by, among other things, the
risks and factors referred to in the Risk Factors section of
Novartis AG's current Form 20-F on file with the US Securities and
Exchange Commission. Novartis is providing the information in this
press release as of this date and does not undertake any obligation
to update any forward-looking statements contained in this press
release as a result of new information, future events or
otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the
evolving needs of patients and societies. Headquartered in Basel,
Switzerland, Novartis offers a diversified portfolio to best meet
these needs: innovative medicines, cost-saving generic and
biosimilar pharmaceuticals and eye care. Novartis has leading
positions globally in each of these areas. In 2016, the Group
achieved net sales of USD 48.5 billion, while R&D throughout
the Group amounted to approximately USD 9.0 billion. Novartis Group
companies employ approximately 121,000 full-time-equivalent
associates. Novartis products are sold in approximately 155
countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow
@Novartis at http://twitter.com/novartis
For Novartis multimedia content, please visit
www.novartis.com/news/media-library
For questions about the site or required registration, please
contact media.relations@novartis.com
# # #
Novartis Media
Relations
Central media line: +41 61 324 2200
E-mail: media.relations@novartis.com
Paul
Barrett
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 797 8137 (mobile)
paul.barrett@novartis.com
Eric Althoff
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
eric.althoff@novartis.com
Antonio Ligi
Novartis Global Media Relations
+41 61 324 1374 (direct)
+41 79 723 3681 (mobile)
antonio.ligi@novartis.com |
Markus
Jaggi
Novartis Media Relations Switzerland
+41 61 324 9577 (direct)
+41 79 673 7433 (mobile)
markus.jaggi@novartis.com
Satoshi Sugimoto
Novartis Media Relations Switzerland
+41 61 324 6129
+41 79 619 2035
satoshi_jean.sugimoto@novartis.com
|
Novartis Investor
Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com
Central |
|
North
America |
|
Samir
Shah |
+41 61
324 7944 |
Richard
Pulik |
+1 212
830 2448 |
Pierre-Michel Bringer |
+41 61
324 1065 |
Cory
Twining |
+1 212
830 2417 |
Thomas
Hungerbuehler |
+41 61
324 8425 |
|
|
Isabella
Zinck |
+41 61
324 7188 |
|
|
Media release (PDF)
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Novartis International AG via Globenewswire
--- End of Message ---
Novartis International AG
P.O. Box Basel Switzerland
WKN: 904278;ISIN: CH0012005267;
Novan (NASDAQ:NOVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novan (NASDAQ:NOVN)
Historical Stock Chart
From Apr 2023 to Apr 2024